EntryPoint Capital LLC Takes $462,000 Position in Electromed, Inc. $ELMD

Key Points

• EntryPoint Capital LLC has acquired a new stake in Electromed, Inc. ($ELMD), purchasing 19,376 shares valued at approximately $462,000, representing about 0.23% of the company's total shares.
• In addition to EntryPoint, several institutional investors, including Bank of America and Russell Investments, have increased their positions in Electromed recently, indicating growing interest in the stock.
• Analysts have set a consensus rating of "Strong Buy" for Electromed, with an average price target of $33.50, reflecting expectations for significant price appreciation.

EntryPoint Capital LLC purchased a new stake in shares of Electromed, Inc. (NYSE:ELMD - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 19,376 shares of the company's stock, valued at approximately $462,000. EntryPoint Capital LLC owned 0.23% of Electromed at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Electromed in the 4th quarter worth $37,000. Bank of America Corp DE increased its stake in shares of Electromed by 179.2% in the 4th quarter. Bank of America Corp DE now owns 4,004 shares of the company's stock worth $118,000 after purchasing an additional 2,570 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Electromed in the 4th quarter worth $119,000. Quantbot Technologies LP increased its stake in shares of Electromed by 57.7% in the 1st quarter. Quantbot Technologies LP now owns 5,301 shares of the company's stock worth $126,000 after purchasing an additional 1,939 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Electromed by 426.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,055 shares of the company's stock worth $149,000 after purchasing an additional 4,095 shares in the last quarter. 40.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on ELMD shares. Wall Street Zen lowered Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley upgraded Electromed to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Roth Capital started coverage on Electromed in a research note on Tuesday, July 22nd. They issued a "buy" rating and a $29.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Strong Buy" and an average target price of $33.50.

Electromed Stock Up 6.6%

ELMD stock traded up $1.25 during trading on Friday, reaching $20.27. The company's stock had a trading volume of 50,766 shares, compared to its average volume of 82,029. The company has a market capitalization of $169.98 million, a P/E ratio of 27.03 and a beta of 0.38. The company's fifty day moving average is $19.64 and its 200-day moving average is $22.44. Electromed, Inc. has a 1 year low of $13.74 and a 1 year high of $35.56.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.